Novartis India has acquired Pfizers’ trademarks ‘Minipress’ and ‘Minipres’ registered in India and certain related intellectual property rights from Pfizer Inc. USA and Pfizer Products Inc. USA for an total aggregate consideration of INR 1250,00,10,000 (One Thousand Two Hundred Fifty Crores and Ten Thousand only)

As per IQVIA MAT July’26 data, Minipress XL recorded revenue of INR 228.6 crores and has been growing at a CAGR of 6.3 % for past four years while the category has been growing at 9 % CAGR for past four years. Minipress XL (containing prazosin) is primarily indicated in India for treating hypertension (high blood pressure) and managing the urinary symptoms of benign prostatic hyperplasia (BPH).

Pfizer’s decision to sell the Minipress brand to Novartis India can primarily be viewed as a strategic portfolio rationalisation and manufacturing-exit decision rather than a reflection of weakness in the brand’s Indian business. Pfizer’s parent company, Pfizer Inc., decided to discontinue manufacturing Minipress XL, making it commercially less attractive for Pfizer to continue supplying and marketing the product in India. Instead of allowing an established brand with a significant Indian customer and physician base to decline, Pfizer chose to monetise the value of its trademarks and related rights by transferring them to Novartis India. Minipress remained a sizeable and established product in the Indian market, generating substantial annual revenue, which made its brand equity valuable even though Pfizer was exiting its manufacturing.

 For Pfizer, the transaction therefore provided an opportunity to realise immediate value from a non-core asset while avoiding the future costs and operational requirements associated with manufacturing and supplying the product. For Novartis India, the acquisition offered an opportunity to obtain an established prescription brand with an existing market presence, physician relationships and revenue base, which could potentially be leveraged through Novartis’s existing commercial and distribution infrastructure.

In this sense, the transaction represents a classic pharmaceutical brand carve-out: Pfizer monetised an asset that no longer fitted its global manufacturing strategy, while Novartis acquired a mature Indian pharmaceutical franchise that it believed could continue generating cash flows over the long term.

Galactik Views